Insider · CIK 0001543112
Morningside Venture Investments Ltd
Files at KZR (Kezar Life Sciences, Inc.), AMLX (Amylyx Pharmaceuticals, Inc.), APMD (Apnimed, Inc.). First filing Jan 5, 2023, latest Aug 5, 2026.
In brief
Morningside Venture Investments Ltd files SEC Form 4 as 10% owner at KZR (Kezar Life Sciences, Inc.), and also at AMLX (Amylyx Pharmaceuticals, Inc.), APMD (Apnimed, Inc.). Since Jan 5, 2023, Morningside Venture Investments Ltd has reported 1 open-market buy worth $5.0M and 17 open-market sells worth $26M, the latest filed on Aug 5, 2026.
A track record needs three past buys with six months of prices behind them; Morningside Venture Investments Ltd has 0, so none is measured yet.
The newest scored trade: bought $5.0M of APMD on Aug 3, 2026, filed Aug 5, 2026, scored 40 (moderate). In the last 12 months: 1 buy worth $5.0M and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
AMLX: Amylyx Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
APMD: Apnimed, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Apnimed, Inc. | $5.0M 312,500 shares | +5% | - | |
| 50Moderate | Amylyx Pharmaceuticals, Inc. | $885k 29,048 shares | -0% | +326% from low-29% from high | |
| 52Moderate | Amylyx Pharmaceuticals, Inc. | $4.9M 160,964 shares | -2% | +344% from low-26% from high | |
| 52Moderate | Amylyx Pharmaceuticals, Inc. | $2.0M 63,448 shares | -1% | +342% from low-26% from high | |
| 41Moderate | Amylyx Pharmaceuticals, Inc. | $297k 9,122 shares | -0% | +368% from low-22% from high | |
| 52Moderate | Amylyx Pharmaceuticals, Inc. | $7.4M 220,714 shares | -3% | +398% from low-17% from high | |
| 52Moderate | Amylyx Pharmaceuticals, Inc. | $1.7M 50,000 shares | -1% | +391% from low-18% from high | |
| 45Moderate | Amylyx Pharmaceuticals, Inc. | $1.7M 50,000 shares | -1% | +428% from low-12% from high | |
| 45Moderate | Amylyx Pharmaceuticals, Inc. | $3.6M 100,000 shares | -1% | +428% from low-12% from high | |
| 29Weak | KZRsell Kezar Life Sciences, Inc. | $454k 65,000 shares | -1% | - | |
| 32Weak | KZRsell Kezar Life Sciences, Inc. | $638k 90,000 shares | -2% | - | |
| 28Weak | KZRsell Kezar Life Sciences, Inc. | $420k 60,000 shares | -1% | - | |
| 27Weak | KZRsell Kezar Life Sciences, Inc. | $343k 50,000 shares | -1% | - | |
| 37Weak | KZRsell Kezar Life Sciences, Inc. | $1.1M 160,000 shares | -3% | - | |
| 18Weak | KZRsell Kezar Life Sciences, Inc. | $42k 6,114 shares | -0% | - | |
| 19Weak | KZRsell Kezar Life Sciences, Inc. | $48k 6,971 shares | -0% | - | |
| 22Weak | KZRsell Kezar Life Sciences, Inc. | $105k 15,162 shares | -0% | - | |
| 28Weak | KZRsell Kezar Life Sciences, Inc. | $396k 55,500 shares | -1% | - |
Transactions
Every row this insider has filed, 43 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | APMD Apnimed, Inc. | CConversion Class A Common Stock | +6,840,213 | - | - | 6,840,213 | Aug 5, 2026 |
| Aug 3, 2026 | APMD Apnimed, Inc. | JOther Class A Common Stock | -6,840,213 | - | - | 0 | Aug 5, 2026 |
| Aug 3, 2026 | APMD Apnimed, Inc. | JOther Common Stock | +6,840,213 | - | - | 6,840,213 | Aug 5, 2026 |
| Aug 3, 2026 | APMD Apnimed, Inc. | POpen-market purchase Common Stock | +312,500 | $16.00 | $5.0M | 7,152,713 | Aug 5, 2026 |
| Aug 3, 2026 | APMD Apnimed, Inc. | CConversion Class A Common Stockindirect: By MVIL, LLC | +75,624 | $14.40 | $1.1M | 75,624 | Aug 5, 2026 |
| Aug 3, 2026 | APMD Apnimed, Inc. | JOther Class A Common Stockindirect: By MVIL, LLC | -75,624 | - | - | 0 | Aug 5, 2026 |
| Aug 3, 2026 | APMD Apnimed, Inc. | JOther Common Stockindirect: By MVIL, LLC | +75,624 | - | - | 75,624 | Aug 5, 2026 |
| Aug 3, 2026 | APMD Apnimed, Inc. | CConversion Convertible Preferred Stockderivative | -9,227,454 | $0.00 | $0 | 0 | Aug 5, 2026 |
| Aug 3, 2026 | APMD Apnimed, Inc. | CConversion Convertible Promissory Notederivativeindirect: By MVIL, LLC | -1,088,986 | $0.00 | $0 | 0 | Aug 5, 2026 |
| Mar 29, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -29,048 | $30.45 | $885k | 6,997,302 | Mar 31, 2023 |
| Mar 27, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -32,964 | $30.25 | $997k | 7,154,350 | Mar 29, 2023 |
| Mar 27, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -28,000 | $30.80 | $862k | 7,126,350 | Mar 29, 2023 |
| Mar 28, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -100,000 | $30.37 | $3.0M | 7,026,350 | Mar 29, 2023 |
| Mar 21, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -34,641 | $31.69 | $1.1M | 7,216,121 | Mar 23, 2023 |
| Mar 21, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -28,807 | $32.17 | $927k | 7,187,314 | Mar 23, 2023 |
| Mar 16, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -9,122 | $32.55 | $297k | 7,250,762 | Mar 17, 2023 |
| Mar 14, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -70,714 | $34.54 | $2.4M | 7,409,884 | Mar 16, 2023 |
| Mar 15, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -108,934 | $33.12 | $3.6M | 7,300,950 | Mar 16, 2023 |
| Mar 15, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -41,066 | $33.68 | $1.4M | 7,259,884 | Mar 16, 2023 |
| Mar 2, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -50,000 | $33.75 | $1.7M | 7,480,598 | Mar 6, 2023 |
| Feb 22, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -47,888 | $34.70 | $1.7M | 7,532,710 | Feb 28, 2023 |
| Feb 22, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,112 | $35.34 | $75k | 7,530,598 | Feb 28, 2023 |
| Feb 22, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -39,916 | $35.91 | $1.4M | 7,640,682 | Feb 24, 2023 |
| Feb 22, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -10,084 | $36.34 | $366k | 7,630,598 | Feb 24, 2023 |
| Feb 23, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -48,889 | $35.55 | $1.7M | 7,581,709 | Feb 24, 2023 |
| Feb 23, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,111 | $36.24 | $40k | 7,580,598 | Feb 24, 2023 |
| Feb 3, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -25,000 | $7.15 | $179k | 5,487,993 | Feb 7, 2023 |
| Feb 6, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -40,000 | $6.88 | $275k | 5,447,993 | Feb 7, 2023 |
| Feb 1, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -40,000 | $6.95 | $278k | 5,562,993 | Feb 3, 2023 |
| Feb 2, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -50,000 | $7.19 | $360k | 5,512,993 | Feb 3, 2023 |
| Jan 30, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -30,000 | $6.91 | $207k | 5,632,993 | Feb 1, 2023 |
| Jan 31, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -30,000 | $7.08 | $212k | 5,602,993 | Feb 1, 2023 |
| Jan 25, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -50,000 | $6.85 | $343k | 5,662,993 | Jan 27, 2023 |
| Jan 23, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -80,000 | $6.81 | $545k | 5,792,993 | Jan 25, 2023 |
| Jan 24, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -80,000 | $6.98 | $558k | 5,712,993 | Jan 25, 2023 |
| Jan 17, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -6,114 | $6.79 | $42k | 5,872,993 | Jan 19, 2023 |
| Jan 12, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -5,000 | $6.77 | $34k | 5,881,078 | Jan 17, 2023 |
| Jan 13, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -1,971 | $7.15 | $14k | 5,879,107 | Jan 17, 2023 |
| Jan 5, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -12,162 | $6.97 | $85k | 5,889,078 | Jan 9, 2023 |
| Jan 6, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -3,000 | $6.89 | $21k | 5,886,078 | Jan 9, 2023 |
| Dec 29, 2022 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -25,000 | $7.10 | $178k | 5,931,740 | Jan 5, 2023 |
| Jan 3, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -500 | $7.10 | $3,550 | 5,931,240 | Jan 5, 2023 |
| Jan 4, 2023 | KZR Kezar Life Sciences, Inc. | SOpen-market sale Common Stock | -30,000 | $7.17 | $215k | 5,901,240 | Jan 5, 2023 |
Questions about Morningside Venture Investments Ltd
Answered from the filings on this page, as of the latest one.
Is Morningside Venture Investments Ltd buying or selling?
In the last 12 months Morningside Venture Investments Ltd reported 1 open-market buy worth $5.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $5.0M of APMD on Aug 3, 2026. Grants, option exercises and tax withholding are not counted.
How did Morningside Venture Investments Ltd's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Morningside Venture Investments Ltd has 0.
Where does Morningside Venture Investments Ltd file Form 4?
Morningside Venture Investments Ltd has filed Form 4 at KZR (Kezar Life Sciences, Inc.); AMLX (Amylyx Pharmaceuticals, Inc.); APMD (Apnimed, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.